Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03386812 Recruiting - Prostate Cancer Clinical Trials

Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer

Start date: October 1, 2017
Phase: N/A
Study type: Observational

The overall goal of this pilot project is to test the hypothesis that a decline in muscle strength precedes the decline in bone strength in men undergoing androgen deprivation therapy (ADT) for prostate cancer. The investigators will measure changes in serum biomarkers involved in muscle-bone crosstalk, anatomic changes in muscle and bone structure and strength that could ultimately contribute to fractures. The findings from this research will inform design of interventions to reduce falls and hip fractures in patients undergoing ADT as well as application to broader populations of at risk patients.

NCT ID: NCT03386045 Not yet recruiting - Prostate Cancer Clinical Trials

Optimal Prostate Study

Start date: February 28, 2018
Phase: N/A
Study type: Interventional

To compare the toxicity, rate of local control, biochemical failure rate and quality of life of three different radiotherapy techniques (moderate hypofractionation, stereotactic body radiotherapy (SBRT) and standard radiotherapy plus 2 fractions of SBRT (BOOSTER)

NCT ID: NCT03385655 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Cancer Biomarker Enrichment and Treatment Selection

Start date: December 30, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.

NCT ID: NCT03384316 Not yet recruiting - Breast Cancer Clinical Trials

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Start date: January 24, 2018
Phase: Phase 1
Study type: Interventional

Background: ETBX-011, ETBX-061, and ETBX-051 are cancer vaccines. Their goal is to teach the immune system to target and kill cancer cells. The vaccines target 3 proteins found in many types of cancer. Researchers think targeting all 3 proteins in unison will have the best results. Objective: To test the safety of combining ETBX-011, ETBX-061, and ETBX-051 and their effects on the immune system. Eligibility: People ages 18 and older with advanced cancer that has not responded to standard therapies Design: Participants will be screened with: Medical history Physical exam Blood, urine, and heart tests Scan: They will lie in a machine that takes pictures of the body. Participants will receive the 3 vaccines through 3 shots under the skin every 3 weeks for 3 doses, then every 8 weeks for up to 1 year. They will have blood and urine tests at each vaccine visit. They will have scans and other measurements of their tumor after 9 weeks and then at their vaccine visits every 8 weeks. Participants will keep a diary of symptoms at the injection site. Participants will have a visit 90 days after their final treatment. This will include a physical exam and blood and urine tests. If they have any ongoing side effects, they will be followed until these end or are not changing. After this visit, they will be called every 3 months for the first year, every 6 months for the next 2 years, then every 12 months for another 2 years to see how they are doing. Participants will have the option to enroll in a long-term follow-up study.

NCT ID: NCT03383107 Not yet recruiting - Breast Cancer Clinical Trials

Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome

Start date: December 30, 2017
Phase: N/A
Study type: Observational

Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells. To test this hypothesis, investigators will take blood samples from subjects undergoing two different standard of care radiation regimens for prostate cancer, and subjects undergoing two different standard of care regimens for breast cancer.

NCT ID: NCT03383016 Recruiting - Prostate Cancer Clinical Trials

Diet, Physical Activity and Related Candidate Biomarkers in Relation to Prostate Cancer Risk (BIOCaPPE)

BIOCaPPE
Start date: June 20, 2013
Phase: N/A
Study type: Observational

The risk of prostate cancer is associated with lifestyle habits, such as diet and physical activity. Indeed, results of numerous studies suggest links between obesity, diabetes, inflammation and androgen and estrogen metabolism in the pathogenesis of prostate cancer. The goal of BIOCaPPE study (Biomarkers and Prostate Cancer/ Prevention and Environment) is to identify biomarkers of prostate cancer risk that are potentially modifiable by environmental exposures (e.g. diet and physical activity). A selection of few of the most promising biological markers will be evaluated in a cohort of more than 3000 men at high-risk of prostate cancer. Such biomarkers would provide a practical approach to identify men at high risk of prostate cancer who could benefit from interventions aiming at reducing their risk. The biomarkers would also be useful to monitor the efficacy of the interventions on patient's lifestyle.

NCT ID: NCT03382522 Not yet recruiting - Prostate Cancer Clinical Trials

Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma

INTEVOPROSTATE
Start date: January 1, 2018
Phase: N/A
Study type: Observational

Prognostic interest of bone scintigraphy in bone metastatic prostate carcinoma (BMPC) has been shown. Recent technological advances allow to perform quantitative bone SPECT-CT in routine practice. The aim of this study is to assess the prognostic interest of quantitative bone SPECT-CT in BMPC.

NCT ID: NCT03381326 Recruiting - Prostate Cancer Clinical Trials

CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

IRSTB030
Start date: December 15, 2014
Phase: N/A
Study type: Observational

Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.

NCT ID: NCT03381105 Recruiting - Prostate Cancer Clinical Trials

From PSA to Stockholm3: Study Part 1

PSA2STHLM3/1
Start date: September 1, 2017
Phase: N/A
Study type: Observational

This part of the project aims to analyze the effectiveness of the Stockholm3 test in regular clinical practice, both in general practice and in the specialist health care, as a tool for detecting patients who need further diagnostics for prostate cancer.

NCT ID: NCT03380806 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Boost Irradiation With Stereotactic Body RT (SBRT)

PBS
Start date: January 1, 2018
Phase: Phase 2
Study type: Interventional

A randomized controlled open-label trial in patients with high risk prostate cancer. Eligible and consenting patients will be randomly allocated to receive stereotactic body radiotherapy (SBRT) boost to prostate or conventional radiotherapy boost to prostate in 1:1 ratio. Prostate radiotherapy boost will be administered after standard pelvic radiotherapy. Subjects will be followed for 24 months post radiation treatment for Quality of Life assessment and toxicity.